ADA 2025 - We are joined by Dr Alice Cheng (University of Toronto, Toronto, CA) to discuss the clinical implications of STRIDE (NCT04560998). The placebo-controlled study investigated whether semaglutide with standard-of-care treatment has an effect on walking ability in patients with PAD and T2D. The primary outcome measure was the change in maximum walking distance on a constant load treadmill test from baseline to the end of treatment at week 52.

Findings showed improved walking distance in patients treated with semaglutide compared to those who received placebo.

Interview Questions:

1. What were the key findings from STRIDE?
2. What clinical criteria should be used to identify patients most likely to benefit from semaglutide based on STRIDE data?
3. How might clinical teams collaborate to integrate semaglutide into a comprehensive PAD treatment pathway?
4. How do the STRIDE results compare with existing studies investigating the effects of semaglutide in similar patient populations?
5. How might the findings from STRIDE influence current guidelines or recommendations for treating patients with PAD and T2D?
6. What additional studies would help clarify the long-term benefits of semaglutide for patients with PAD and T2D?

Recorded remotely from Toronto, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographer: Oliver Miles

Support: This is an independent interview produced by Radcliffe CVRM.